Статті в журналах з теми "Leeds melanoma Cohort"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-48 статей у журналах для дослідження на тему "Leeds melanoma Cohort".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Newton-Bishop, Julia A., Samantha Beswick, Juliette Randerson-Moor, Yu-Mei Chang, Paul Affleck, Faye Elliott, May Chan, et al. "Serum 25-Hydroxyvitamin D3 Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma." Journal of Clinical Oncology 27, no. 32 (November 10, 2009): 5439–44. http://dx.doi.org/10.1200/jco.2009.22.1135.
Повний текст джерелаNewton Bishop, J. A., S. Beswick, J. Randerson-Moor, Y. Chang, P. Affleck, F. Elliott, D. Elder, J. Barrett, and T. Bishop. "Serum vitamin D levels, VDR, and survival from melanoma." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 9016. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.9016.
Повний текст джерелаNewton‐Bishop, Julia A., John R. Davies, Faheem Latheef, Juliette Randerson‐Moor, May Chan, Jo Gascoyne, Saila Waseem, Susan Haynes, Charles O'Donovan, and D. Timothy Bishop. "25‐Hydroxyvitamin D 2 /D 3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort." International Journal of Cancer 136, no. 12 (December 13, 2014): 2890–99. http://dx.doi.org/10.1002/ijc.29334.
Повний текст джерелаEmran, Abdullah Al, Jérémie Nsengimana, Gaya Punnia-Moorthy, Ulf Schmitz, Stuart J. Gallagher, Julia Newton-Bishop, Jessamy C. Tiffen, and Peter Hersey. "Study of the Female Sex Survival Advantage in Melanoma—A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts." Cancers 12, no. 8 (July 28, 2020): 2082. http://dx.doi.org/10.3390/cancers12082082.
Повний текст джерелаBoon, Ian S., Peter Bownes, Shirin Namini, Carolyn Richardson, and Satiavani Ramasamy. "Implementation of high dose rate (HDR) skin brachytherapy using the Valencia applicator: Leeds Cancer Centre non-melanoma cohort." Clinical Oncology 31 (October 2019): e15. http://dx.doi.org/10.1016/j.clon.2019.09.042.
Повний текст джерелаWang, Minyu, Soroor Zadeh, Angela Pizzolla, Kevin Thia, David E. Gyorki, Grant A. McArthur, Richard A. Scolyer, et al. "Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation." Journal for ImmunoTherapy of Cancer 10, no. 4 (April 2022): e004095. http://dx.doi.org/10.1136/jitc-2021-004095.
Повний текст джерелаHassel, Jessica Cecile, Heiko Smetak, Martin Salzmann, Matthias Haefner, Denise Bernhardt, Ingrid Hülsmeyer, Alexander Enk, Juergen Debus, and Philipp Beckhove. "Evaluation of radiotherapeutic and immune-modulatory response to whole brain radiotherapy or stereotactic radiosurgery in patients with brain metastases from malignant melanoma treated with or without ipilimumab (ELEKTRA)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e14104-e14104. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14104.
Повний текст джерелаShah, Hemali, Paul Feustel, and Lindy Davis. "Survivorship care plans and adherence with surveillance schedule in patients with invasive melanoma." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e24079-e24079. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e24079.
Повний текст джерелаMeador, Lydia, Hari Menon, Haiyan Cui, Denise J. Roe, David J. DiCaudo, and Karen Taraszka Hastings. "Inflammation induces GILT expression in human melanoma." Journal of Immunology 200, no. 1_Supplement (May 1, 2018): 178.28. http://dx.doi.org/10.4049/jimmunol.200.supp.178.28.
Повний текст джерелаBrendlin, Andreas Stefan, Felix Peisen, Haidara Almansour, Saif Afat, Thomas Eigentler, Teresa Amaral, Sebastian Faby, Adria Font Calvarons, Konstantin Nikolaou, and Ahmed E. Othman. "A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma." Journal for ImmunoTherapy of Cancer 9, no. 11 (November 2021): e003261. http://dx.doi.org/10.1136/jitc-2021-003261.
Повний текст джерелаAmaro, Adriana, Michela Croce, Silvano Ferrini, Gaia Barisione, Marina Gualco, Patrizia Perri, Ulrich Pfeffer, et al. "Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition." Cancers 12, no. 6 (June 4, 2020): 1468. http://dx.doi.org/10.3390/cancers12061468.
Повний текст джерелаNarous, M., Z. Nugent, H. Singh, and C. N. Bernstein. "A164 RISKS OF SKIN CANCERS PRE- AND POST-INFLAMMATORY BOWEL DISEASE DIAGNOSIS." Journal of the Canadian Association of Gastroenterology 5, Supplement_1 (February 21, 2022): 42–43. http://dx.doi.org/10.1093/jcag/gwab049.163.
Повний текст джерелаKuan, Feng-Che, Chung-Sheng Shi, and Meng-Hung Lin. "Correlation of BRAF genomic alterations with higher mutation burden and predictive response to immune checkpoint inhibitors among human malignancies." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e14589-e14589. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e14589.
Повний текст джерелаKuan, Feng-Che, Chung-Sheng Shi, and Meng-Hung Lin. "Correlation of BRAF genomic alterations with higher mutation burden and predictive response to immune checkpoint inhibitors among human malignancies." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e14589-e14589. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e14589.
Повний текст джерелаChampiat, Stephane, Martin Wermke, Johann de Bono, Aurelien Marabelle, Christiane Jungels, Cécile Vicier, Norbert Vey, et al. "Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT188. http://dx.doi.org/10.1158/1538-7445.am2022-ct188.
Повний текст джерелаGeorge, Thomas J., Ji-Hyun Lee, Peter Joel Hosein, David L. DeRemer, Jonathan Alexander Chatzkel, Brian Hemendra Ramnaraign, Sherise C. Rogers, et al. "Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 3122. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3122.
Повний текст джерелаGeorge, Thomas J., Ji-Hyun Lee, Peter Joel Hosein, David L. DeRemer, Jonathan Alexander Chatzkel, Brian Hemendra Ramnaraign, Sherise C. Rogers, et al. "Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 3122. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3122.
Повний текст джерелаBeasley, Georgia, Nellie Farrow, Karenia Landa, Maria Angelica Seilm, Sin-Ho Jung, Darell Bigner, Andrea True Kelly, Smita Nair, Matthias Gromeier, and April Salama. "302 A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A329. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0302.
Повний текст джерелаPark, Jong Chul, Hatem Soliman, Gerald Falchook, Taofeek Owonikoko, Anna Spreafico, Erminia Massarelli, Meredith McKean, et al. "511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A542. http://dx.doi.org/10.1136/jitc-2021-sitc2021.511.
Повний текст джерелаBeasley, Georgia M., Smita K. Nair, Norma E. Farrow, Karenia Landa, Maria Angelica Selim, Carol Ann Wiggs, Sin-Ho Jung, et al. "Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma." Journal for ImmunoTherapy of Cancer 9, no. 4 (April 2021): e002203. http://dx.doi.org/10.1136/jitc-2020-002203.
Повний текст джерелаOwonikoko, Taofeek K., Justin C. Moser, Janet Yoon, Emily K. Slotkin, Afshin Dowlati, Vincent T. Ma, Maria Düring, and Joen Sveistrup. "Phase 1 trial of GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): TPS3162. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps3162.
Повний текст джерелаRicart, A. D., M. Cooney, J. Sarantopoulos, J. Brell, K. W. Locke, R. E. Gammans, G. Medina, A. Zambito, A. W. Tolcher, and S. C. Remick. "A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 3096. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3096.
Повний текст джерелаPollack, Megan, Allison Shayna Betof, Katherine Rappazzo, Ian Valentine, Zeynep Eroglu, Douglas Buckner Johnson, and Alexander Noor Shoushtari. "Safety of resuming anti-PD-1 (aPD1) in patients (pts) with immune-related adverse events (irAEs) during combined anti-CTLA-4 (aCTLA4) and aPD1 in metastatic melanoma (MM)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 9544. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9544.
Повний текст джерелаPortuguese, Andrew J., Scott S. Tykodi, Christopher D. Blosser, Ted A. Gooley, John A. Thompson, and Evan T. Hall. "Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review." Journal of the National Comprehensive Cancer Network 20, no. 4 (April 2022): 406–16. http://dx.doi.org/10.6004/jnccn.2022.7009.
Повний текст джерелаGreif, Philipp A., Sebastian H. Eck, Nikola Konstandin, Anna Benet-Pages, Annika Dufour, Anna Vetter, Henning Popp, et al. "Identification of Recurring Tumor-Specific Somatic Mutations In Acute Myeloid Leukemia by Transcriptome Sequencing." Blood 116, no. 21 (November 19, 2010): 1059. http://dx.doi.org/10.1182/blood.v116.21.1059.1059.
Повний текст джерелаBothwell, Mia, Aaron Cheng, Leyre Zubiri, Meghan Mooradian, Yevgeniy R. Semenov, Gayle C. Blouin, Erica Tavares, et al. "Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 2655. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2655.
Повний текст джерелаBodei, Lisa, Petr Kavan, Moishe Liberman, Neil Taunk, Ur Metser, Daniel Juneau, Eileen Mary O'Reilly, Junsheng Ma, Richard Cioci, and Albiruni Ryan Abdul Razak. "FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): TPS3161. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps3161.
Повний текст джерелаPurroy, Noelia, Nicholas Durham, Marc Phillips, Maureen M. Hattersley, Lindsey Jung, Diwakar Davar, Dmitriy Zamarin, Tanner M. Johanns, and Igor Puzanov. "Abstract CT218: First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT218. http://dx.doi.org/10.1158/1538-7445.am2022-ct218.
Повний текст джерелаCoupe, Nicholas, Ian B. Walters, Robert A. Kramer, Uzi Gileadi, and Mark R. Middleton. "A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL)." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 2582. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.2582.
Повний текст джерелаGiovannini, I., R. Agarinis, S. Cacioppo, S. Sacco, G. De Marchi, E. DI Poi, A. Zabotti, L. Quartuccio, and S. De Vita. "AB0490 PREVALENCE OF RISK FACTORS FOR CARDIOVASCULAR EVENTS, MALIGNANCY OR THROMBOEMBOLIC EVENTS IN RHEUMATOID ARTHRITIS UNDER JAK INHIBITORS IN A REAL-LIFE MONOCENTRIC COHORT." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1439.2–1440. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5908.
Повний текст джерелаLowndes, S. A., A. Adams, A. Timms, M. Middleton, C. Hayward, S. D. Reich, A. P. Mazar, and A. L. Harris. "Phase I study of ATN-224 in patients (pts) with advanced solid tumours." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 2065. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.2065.
Повний текст джерелаKnorr, David, Jeffrey Ravetch, Gabriela D’Andrea, Linda Vahdat, Christopher Klebanoff, and Mark Robson. "496 Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A528. http://dx.doi.org/10.1136/jitc-2021-sitc2021.496.
Повний текст джерелаHamid, Omid, Melissa L. Johnson, Jason Luke, Richard T. Maziarz, Jamie Merchan, Emerson E. Lim, Sandip P. Patel, et al. "Abstract CT187: Phase 1 Trial of RTX-240, allogeneic red blood cells engineered to express 4-1BBL and trans-presented IL-15, in patients (Pts) with advanced solid tumors." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT187. http://dx.doi.org/10.1158/1538-7445.am2022-ct187.
Повний текст джерелаAllen, Ian Matthew, Yonina Robbie Murciano-Goroff, Leyre Zubiri, Qun Li, Michael Sang Hughes, Marko Velimirovic, Jacqueline N. Chu, et al. "Flu vaccination rate of patients with severe immune-related adverse events." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e18234-e18234. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18234.
Повний текст джерелаFugere, Brad, Jim Zhongning Chen, Farah Mazahreh, Tyler Fugere, Liyan Mazahreh, and A. Mazin Safar. "Weight loss (WL) as a predictive factor for immune oncology (IO)." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): e14528-e14528. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14528.
Повний текст джерелаChen, Szu-Ying, Ons Mamai, and Rosemary Akhurst. "Abstract 3420: Tgfbm3b is a natural germline genetic variant that modifies anti-tumor responses to anti-PD-1 immunotherapy through its action on the tumor microenvironment." Cancer Research 82, no. 12_Supplement (June 15, 2022): 3420. http://dx.doi.org/10.1158/1538-7445.am2022-3420.
Повний текст джерелаChawla, Sant P., Victoria S. Chua, Erlinda M. Gordon, John Cini, Susan Dexter, Manual DaFonseca, Justus Bingham, Grantham W. Hogeland, and Richard T. Kenney. "Abstract CT245: Clinical development of a novel form of interleukin-12 with extended pharmacokinetics." Cancer Research 83, no. 8_Supplement (April 14, 2023): CT245. http://dx.doi.org/10.1158/1538-7445.am2023-ct245.
Повний текст джерелаCrespin, Athéna, Pierre-Alain Bandinelli, Clément Le Bescop, Renaud Buffet, Jean De Gunzburg, Fabien Vitry, Gérard Zalcman, and Julie Cervesi. "278 Systematic review and meta-analysis evaluating the impact of antibiotic use on clinical outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A301—A302. http://dx.doi.org/10.1136/jitc-2021-sitc2021.278.
Повний текст джерелаTogami, Katsuhiro, Sun Sook Chung, Vikas Madan, Christopher M. Kenyon, Lucia Cabal-Hierro, Justin Taylor, Sunhee Kim, et al. "Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis." Blood 136, Supplement 1 (November 5, 2020): 13–14. http://dx.doi.org/10.1182/blood-2020-137727.
Повний текст джерелаJain, Nitin, Alessandra Ferrajoli, Musa Yilmaz, Philip A. Thompson, Marina Konopleva, Michael R. Green, Deepa Sampath, et al. "Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)." Blood 138, Supplement 1 (November 5, 2021): 2626. http://dx.doi.org/10.1182/blood-2021-154195.
Повний текст джерелаSeviiri, Mathias, Richard A. Scolyer, D. Timothy Bishop, Julia A. Newton-Bishop, Mark M. Iles, Serigne N. Lo, Johnathan R. Stretch, et al. "Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting." Journal of Translational Medicine 20, no. 1 (September 5, 2022). http://dx.doi.org/10.1186/s12967-022-03613-2.
Повний текст джерелаCastro, María Victoria, Gastón Alexis Barbero, María Belén Villanueva, Luca Grumolato, Jérémie Nsengimana, Julia Newton-Bishop, Edith Illescas, María Josefina Quezada, and Pablo Lopez-Bergami. "ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation." Journal of Biomedical Science 28, no. 1 (November 13, 2021). http://dx.doi.org/10.1186/s12929-021-00776-w.
Повний текст джерелаFarlow, Janice L., Scott A. McLean, Nithin Peddireddy, Carol R. Bradford, Kelly M. Malloy, Chaz L. Stucken, Kyle K. VanKoevering, Matthew E. Spector, and Andrew J. Rosko. "Impact of Completion Lymphadenectomy on Quality of Life for Head and Neck Cutaneous Melanoma." Otolaryngology–Head and Neck Surgery, April 20, 2021, 019459982110074. http://dx.doi.org/10.1177/01945998211007442.
Повний текст джерелаUrbanski, Alexander, Julia Minnemann, Cornelia Mauch, Thomas Schmidt, Nicole Kreuzberg, Max Schlaak, Christiane J. Bruns, Dirk L. Stippel, and Roger Wahba. "Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis." Langenbeck's Archives of Surgery 408, no. 1 (January 21, 2023). http://dx.doi.org/10.1007/s00423-023-02804-9.
Повний текст джерелаZhang, Wancong, Xuqi Xie, Zijian Huang, Xiaoping Zhong, Yang Liu, Kit-Leong Cheong, Jianda Zhou, and Shijie Tang. "The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM." Frontiers in Immunology 13 (September 23, 2022). http://dx.doi.org/10.3389/fimmu.2022.919145.
Повний текст джерелаXu, Zhangling, Xia Lv, Wenwen Xu, Yan Ye, Xiaodong Wang, Shuang Ye, Huihua Ding, and Wanlong Wu. "Spontaneous Intramuscular Hemorrhage in Anti-MDA5 Positive Dermatomyositis: A Case Series and Literature Review." Frontiers in Medicine 8 (January 24, 2022). http://dx.doi.org/10.3389/fmed.2021.802753.
Повний текст джерелаVereecke, Gertjan, Justine Defreyne, Dorien Van Saen, Sarah Collet, Jo Van Dorpe, Guy T'Sjoen, and Ellen Goossens. "Characterisation of testicular function and spermatogenesis in transgender women." Human Reproduction, November 30, 2020. http://dx.doi.org/10.1093/humrep/deaa254.
Повний текст джерелаPeleva, Emilia, Yue Chen, Hasan Rizvi, Catherine Harwood, and Jun Wang. "010 Enhanced outcome prediction in cutaneous squamous cell carcinoma using deep-learning and computational histopathology (cSCCnet)." British Journal of Dermatology 188, Supplement_4 (June 2023). http://dx.doi.org/10.1093/bjd/ljad113.010.
Повний текст джерела